PriceTargets.com logo

Thermo Fisher Scientific - TMO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $649.33
  • Forecasted Upside: 21.82%
  • Number of Analysts: 22
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 17 Buy Ratings
  • 1 Strong Buy Ratings
$533.02 As of 11/14/2024 01:00 AM ET
▼ -8.88 (-1.64%)

This chart shows the closing price for TMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Thermo Fisher Scientific Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMO

Analyst Price Target is $649.33
▲ +21.82% Upside Potential
This price target is based on 22 analysts offering 12 month price targets for Thermo Fisher Scientific in the last 3 months. The average price target is $649.33, with a high forecast of $718.00 and a low forecast of $575.00. The average price target represents a 21.82% upside from the last price of $533.02.

This chart shows the closing price for TMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 22 contributing investment analysts is to moderate buy stock in Thermo Fisher Scientific. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/24/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 14 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/15/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2024

Latest Recommendations

  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/24/2024Sanford C. BernsteinLower TargetMarket Perform ➝ Market Perform$625.00 ➝ $620.00
10/24/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$767.00 ➝ $718.00
10/24/2024Stifel NicolausLower TargetBuy ➝ Buy$680.00 ➝ $665.00
10/24/2024Evercore ISILower TargetOutperform ➝ Outperform$630.00 ➝ $620.00
10/24/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$670.00 ➝ $660.00
10/24/2024Robert W. BairdLower TargetOutperform ➝ Outperform$632.00 ➝ $622.00
10/23/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$620.00 ➝ $610.00
10/22/2024TD CowenBoost Target$656.00 ➝ $686.00
10/22/2024Bernstein BankBoost TargetMarket Perform ➝ Market Perform$565.00 ➝ $625.00
10/15/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$600.00 ➝ $620.00
10/14/2024Redburn AtlanticInitiated CoverageBuy$680.00
10/1/2024Evercore ISIBoost TargetOutperform ➝ Outperform$605.00 ➝ $630.00
10/1/2024StephensInitiated CoverageOverweight$680.00
9/20/2024Stifel NicolausBoost TargetBuy ➝ Buy$615.00 ➝ $680.00
9/20/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$650.00 ➝ $670.00
9/20/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$655.00 ➝ $680.00
9/20/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$767.00 ➝ $767.00
9/16/2024UBS GroupUpgradeStrong-Buy
9/16/2024Bank of AmericaBoost TargetBuy ➝ Buy$600.00 ➝ $675.00
8/27/2024Wells Fargo & CompanyInitiated CoverageOverweight$670.00
7/25/2024TD CowenBoost TargetBuy ➝ Buy$648.00 ➝ $658.00
7/25/2024Raymond JamesBoost TargetOutperform ➝ Outperform$650.00 ➝ $660.00
7/25/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$660.00 ➝ $664.00
7/25/2024Stifel NicolausBoost TargetBuy ➝ Buy$600.00 ➝ $615.00
7/25/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$620.00 ➝ $632.00
7/2/2024Evercore ISILower TargetOutperform ➝ Outperform$615.00 ➝ $600.00
6/28/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$615.00 ➝ $600.00
6/3/2024Jefferies Financial GroupReiterated RatingHold ➝ Buy$600.00 ➝ $650.00
4/30/2024HSBCBoost TargetBuy ➝ Buy$660.00 ➝ $670.00
4/25/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$590.00 ➝ $615.00
4/25/2024Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$600.00 ➝ $610.00
4/25/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$600.00 ➝ $650.00
4/25/2024Robert W. BairdLower TargetOutperform ➝ Outperform$621.00 ➝ $620.00
4/17/2024HSBCBoost TargetBuy ➝ Buy$630.00 ➝ $660.00
4/10/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$550.00 ➝ $640.00
4/4/2024Evercore ISIBoost TargetOutperform ➝ Outperform$575.00 ➝ $610.00
3/18/2024CitigroupInitiated CoverageNeutral$620.00
2/1/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$592.00 ➝ $642.00
2/1/2024Raymond JamesBoost TargetOutperform ➝ Outperform$515.00 ➝ $605.00
1/24/2024BarclaysDowngradeOverweight ➝ Equal Weight$475.00 ➝ $555.00
1/8/2024Sanford C. BernsteinReiterated RatingOutperform ➝ Market Perform
12/18/2023HSBCInitiated CoverageBuy$610.00
12/14/2023Robert W. BairdReiterated RatingOutperform ➝ Outperform$670.00
12/13/2023Wolfe ResearchInitiated CoverageOutperform$575.00
12/11/2023CitigroupBoost TargetBuy ➝ Buy$530.00 ➝ $575.00
10/26/2023Stifel NicolausLower TargetBuy ➝ Buy$660.00 ➝ $530.00
10/26/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$657.00 ➝ $579.00
10/26/2023CitigroupLower TargetBuy ➝ Buy$625.00 ➝ $530.00
10/26/2023Raymond JamesLower TargetOutperform ➝ Outperform$580.00 ➝ $515.00
10/26/2023KeyCorpDowngradeOverweight ➝ Sector Weight
10/25/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$475.00
10/24/2023Morgan StanleyLower TargetOverweight ➝ Overweight$640.00 ➝ $600.00
10/18/2023Raymond JamesLower TargetOutperform ➝ Outperform$630.00 ➝ $580.00
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$670.00 ➝ $630.00
10/2/2023CitigroupReiterated RatingBuy ➝ Buy$625.00
9/29/2023BarclaysLower Target$625.00 ➝ $585.00
9/28/2023Sanford C. BernsteinInitiated CoverageOutperform$603.00
9/6/2023CitigroupInitiated CoverageBuy ➝ Buy$625.00
7/28/2023Wells Fargo & CompanyBoost TargetUnderweight$505.00 ➝ $520.00
7/28/2023Raymond JamesBoost TargetOutperform$595.00 ➝ $630.00
7/27/2023Royal Bank of CanadaBoost Target$662.00 ➝ $698.00
7/27/2023JPMorgan Chase & Co.Boost Target$660.00 ➝ $670.00
7/27/2023Robert W. BairdLower TargetOutperform$664.00 ➝ $625.00
7/27/2023BarclaysBoost TargetOverweight$590.00 ➝ $625.00
7/19/2023Robert W. BairdLower TargetOutperform$670.00 ➝ $664.00
7/18/2023Raymond JamesInitiated CoverageOutperform$595.00
7/13/2023Credit Suisse GroupUpgradeNeutral ➝ Outperform$620.00
6/27/2023BarclaysLower Target$610.00 ➝ $590.00
5/25/2023KeyCorpLower Target$710.00 ➝ $640.00
5/25/2023JPMorgan Chase & Co.Lower Target$675.00 ➝ $660.00
4/27/2023CitigroupLower Target$700.00 ➝ $650.00
4/27/2023Morgan StanleyLower Target$670.00 ➝ $620.00
4/27/2023Robert W. BairdLower Target$693.00 ➝ $670.00
4/27/2023BarclaysLower Target$625.00 ➝ $610.00
4/4/2023Evercore ISILower TargetOutperform$615.00 ➝ $610.00
4/4/2023BarclaysLower TargetOverweight$660.00 ➝ $625.00
2/2/2023Leerink PartnersBoost TargetOutperform$620.00 ➝ $630.00
2/2/2023Morgan StanleyBoost TargetOverweight$613.00 ➝ $670.00
2/2/2023CowenBoost TargetOutperform$690.00 ➝ $711.00
2/2/2023Robert W. BairdLower Target$710.00 ➝ $693.00
2/2/2023BarclaysBoost TargetOverweight$630.00 ➝ $660.00
2/2/2023CitigroupBoost TargetBuy$650.00 ➝ $700.00
1/24/2023BarclaysBoost TargetOverweight$570.00 ➝ $630.00
1/6/2023Leerink PartnersBoost TargetOutperform$555.00 ➝ $620.00
1/3/2023Wells Fargo & CompanyLower TargetUnderweight$525.00 ➝ $505.00
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$620.00
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform$661.00
11/29/2022BarclaysLower TargetOverweight$575.00 ➝ $570.00
10/27/2022Credit Suisse GroupLower Target$620.00
10/27/2022Morgan StanleyLower TargetOverweight$678.00 ➝ $613.00
10/27/2022Robert W. BairdLower TargetOutperform$711.00 ➝ $696.00
10/27/2022CitigroupLower TargetBuy$715.00 ➝ $650.00
10/27/2022BenchmarkDowngradeBuy ➝ Hold
10/27/2022BarclaysLower TargetOverweight$595.00 ➝ $575.00
10/27/2022Leerink PartnersLower TargetOutperform$590.00 ➝ $555.00
9/12/2022BarclaysLower TargetOverweight$685.00 ➝ $595.00
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$675.00
8/9/2022BarclaysBoost Target$685.00
8/1/2022BarclaysBoost TargetOverweight$630.00 ➝ $685.00
7/29/2022Morgan StanleyBoost TargetOverweight$670.00 ➝ $678.00
7/29/2022Leerink PartnersBoost TargetOutperform$630.00 ➝ $650.00
7/13/2022BarclaysLower TargetOverweight$675.00 ➝ $630.00
4/25/2022Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$605.00 ➝ $525.00
2/3/2022BTIG ResearchReiterated RatingBuy$718.00
2/3/2022Wells Fargo & CompanyLower TargetEqual Weight$700.00 ➝ $605.00
1/26/2022BarclaysInitiated CoverageOverweight ➝ Overweight$700.00
12/14/2021Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$625.00 ➝ $700.00
10/28/2021Morgan StanleyInitiated CoverageOverweight
10/28/2021Robert W. BairdBoost TargetOutperform$635.00 ➝ $657.00
10/28/2021CitigroupBoost TargetBuy$700.00 ➝ $715.00
10/28/2021Leerink PartnersBoost TargetOutperform ➝ Outperform$675.00 ➝ $685.00
10/20/2021CitigroupUpgradeNeutral ➝ Buy$620.00 ➝ $700.00
10/14/2021CowenBoost TargetOutperform$655.00 ➝ $696.00
9/23/2021The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
9/23/2021CowenBoost TargetOutperform$560.00 ➝ $655.00
9/22/2021BenchmarkBoost TargetPositive ➝ Buy$580.00 ➝ $650.00
9/22/2021BTIG ResearchBoost TargetBuy$610.00 ➝ $700.00
9/21/2021UBS GroupBoost TargetBuy$595.00 ➝ $670.00
9/20/2021Jefferies Financial GroupInitiated CoverageHold$540.00
9/20/2021Leerink PartnersBoost TargetOutperform$600.00 ➝ $675.00
9/20/2021KeyCorpBoost TargetOverweight$555.00 ➝ $710.00
9/20/2021JPMorgan Chase & Co.Boost TargetOverweight$600.00 ➝ $700.00
9/20/2021CitigroupBoost TargetNeutral$535.00 ➝ $620.00
8/4/2021ArgusBoost TargetAverage ➝ Buy$530.00 ➝ $600.00
7/29/2021CowenBoost TargetOutperform$525.00 ➝ $560.00
7/29/2021BTIG ResearchBoost TargetBuy$590.00 ➝ $610.00
7/19/2021Leerink PartnersReiterated RatingOutperform
7/16/2021BenchmarkInitiated CoverageBuy$580.00
7/12/2021KeyCorpBoost TargetOverweight$520.00 ➝ $555.00
6/23/2021Robert W. BairdBoost TargetPositive ➝ Outperform$545.00 ➝ $550.00
6/15/2021The Goldman Sachs GroupLower TargetBuy$590.00 ➝ $530.00
5/3/2021Robert W. BairdReiterated RatingBuy
4/16/2021Evercore ISIBoost TargetOutperform$525.00 ➝ $540.00
3/29/2021UBS GroupLower TargetBuy$588.00 ➝ $560.00
3/18/2021KeyCorpUpgradeSector Weight ➝ Overweight$520.00
3/8/2021BarclaysInitiated CoverageOverweight$525.00
3/2/2021BarclaysInitiated CoverageOverweight$525.00
2/3/2021BTIG ResearchBoost TargetBuy$540.00 ➝ $590.00
2/2/2021CitigroupBoost TargetBuy$500.00 ➝ $530.00
2/2/2021Stifel NicolausBoost TargetBuy$530.00 ➝ $600.00
2/2/2021CowenBoost TargetOutperform$525.00 ➝ $585.00
2/2/2021Morgan StanleyBoost TargetOverweight$535.00 ➝ $575.00
2/2/2021UBS GroupBoost TargetPositive ➝ Buy$566.00 ➝ $588.00
2/2/2021Leerink PartnersBoost TargetOutperform$525.00 ➝ $560.00
1/12/2021Credit Suisse GroupBoost Target$556.00 ➝ $580.00
1/8/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$490.00 ➝ $556.00
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral
12/2/2020Credit Suisse GroupBoost TargetNeutral$488.00 ➝ $490.00
12/2/2020Robert W. BairdBoost TargetOutperform$512.00 ➝ $523.00
12/2/2020The Goldman Sachs GroupInitiated CoverageBuy$570.00
11/9/2020KeyCorpInitiated CoverageSector Weight ➝ Sector Weight$550.00
10/27/2020Needham & Company LLCBoost TargetBuy$477.00 ➝ $539.00
10/22/2020BTIG ResearchBoost TargetPositive ➝ Buy$475.00 ➝ $540.00
10/22/2020Robert W. BairdBoost TargetOutperform$481.00 ➝ $512.00
10/22/2020Credit Suisse GroupBoost TargetNeutral$432.00 ➝ $488.00
10/22/2020Morgan StanleyBoost TargetOverweight$485.00 ➝ $535.00
10/22/2020Leerink PartnersBoost TargetOutperform$470.00 ➝ $525.00
10/5/2020JPMorgan Chase & Co.Boost TargetOverweight$460.00 ➝ $480.00
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$494.00
9/17/2020Needham & Company LLCBoost TargetBuy$468.00 ➝ $477.00
9/14/2020Morgan StanleyInitiated CoverageOverweight$485.00
9/11/2020Bank of AmericaBoost TargetBuy$460.00 ➝ $480.00
9/11/2020Credit Suisse GroupBoost TargetNeutral$425.00 ➝ $432.00
9/11/2020Leerink PartnersBoost TargetOutperform$455.00 ➝ $470.00
9/11/2020CitigroupBoost TargetBuy$471.00 ➝ $485.00
8/21/2020Credit Suisse GroupBoost TargetNeutral$405.00 ➝ $425.00
8/20/2020JPMorgan Chase & Co.Reiterated RatingOverweight$460.00
8/13/2020Needham & Company LLCInitiated CoverageBuy$468.00
7/27/2020ArgusBoost Target$370.00 ➝ $450.00
7/23/2020Robert W. BairdBoost Target$352.00 ➝ $436.00
7/23/2020Needham & Company LLCBoost TargetBuy$415.00 ➝ $468.00
7/23/2020BTIG ResearchBoost TargetBuy$372.00 ➝ $475.00
7/23/2020CitigroupBoost TargetBuy$390.00 ➝ $471.00
7/23/2020Stifel NicolausBoost TargetHold ➝ Buy$370.00 ➝ $460.00
7/23/2020Leerink PartnersBoost TargetOutperform$365.00 ➝ $455.00
7/21/2020UBS GroupBoost TargetBuy$385.00 ➝ $440.00
7/7/2020Needham & Company LLCBoost TargetBuy$383.00 ➝ $415.00
7/6/2020CowenReiterated RatingBuy$380.00
4/23/2020CitigroupBoost TargetBuy$365.00 ➝ $390.00
4/23/2020Leerink PartnersBoost TargetOutperform$330.00 ➝ $365.00
4/23/2020Needham & Company LLCBoost Target$341.00 ➝ $383.00
4/22/2020Needham & Company LLCBoost TargetBuy$341.00 ➝ $383.00
4/21/2020Wells Fargo & CompanyBoost TargetEqual Weight$300.00 ➝ $340.00
4/2/2020Stifel NicolausLower TargetBuy$345.00 ➝ $315.00
3/30/2020Wells Fargo & CompanyLower TargetEqual Weight$345.00 ➝ $300.00
3/20/2020CitigroupLower TargetBuy$390.00 ➝ $365.00
3/4/2020Robert W. BairdBoost TargetOutperform$340.00 ➝ $341.00
2/24/2020ArgusReiterated RatingBuy ➝ Positive$370.00
1/31/2020BTIG ResearchBoost TargetBuy ➝ In-Line$342.00 ➝ $372.00
1/31/2020Robert W. BairdBoost TargetOutperform$319.00 ➝ $340.00
1/31/2020Wells Fargo & CompanyLower TargetEqual Weight$350.00 ➝ $345.00
1/31/2020Needham & Company LLCBoost TargetBuy$331.00 ➝ $341.00
1/31/2020CitigroupBoost TargetBuy$380.00 ➝ $390.00
1/22/2020Credit Suisse GroupInitiated CoverageNeutral$341.00
1/7/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$350.00
1/6/2020CitigroupInitiated CoverageBuy$380.00
1/6/2020CowenReiterated RatingOutperform$330.00 ➝ $365.00
1/3/2020Needham & Company LLCInitiated CoverageStrong-Buy$271.00
(Data available from 11/15/2019 forward)

News Sentiment Rating

1.24 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 32 very positive mentions
  • 18 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 42 very positive mentions
  • 25 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/19/2024
  • 36 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2024
  • 33 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
7/18/2024
  • 45 very positive mentions
  • 25 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/17/2024
  • 29 very positive mentions
  • 16 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/16/2024
  • 39 very positive mentions
  • 20 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/16/2024
  • 84 very positive mentions
  • 28 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
11/15/2024

Current Sentiment

  • 84 very positive mentions
  • 28 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Thermo Fisher Scientific logo
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $533.02
Low: $531.69
High: $542.38

50 Day Range

MA: $589.87
Low: $540.63
High: $624.21

52 Week Range

Now: $533.02
Low: $463.99
High: $627.88

Volume

1,747,398 shs

Average Volume

1,462,991 shs

Market Capitalization

$203.88 billion

P/E Ratio

33.42

Dividend Yield

0.29%

Beta

0.79

Frequently Asked Questions

What sell-side analysts currently cover shares of Thermo Fisher Scientific?

The following Wall Street analysts have issued stock ratings on Thermo Fisher Scientific in the last year: Bank of America Co., Barclays PLC, Bernstein Bank, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Raymond James, Redburn Atlantic, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Stephens, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for TMO.

What is the current price target for Thermo Fisher Scientific?

0 Wall Street analysts have set twelve-month price targets for Thermo Fisher Scientific in the last year. Their average twelve-month price target is $649.33, suggesting a possible upside of 21.8%. Royal Bank of Canada has the highest price target set, predicting TMO will reach $718.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $575.00 for Thermo Fisher Scientific in the next year.
View the latest price targets for TMO.

What is the current consensus analyst rating for Thermo Fisher Scientific?

Thermo Fisher Scientific currently has 4 hold ratings, 17 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TMO.

What other companies compete with Thermo Fisher Scientific?

Other companies that are similar to Thermo Fisher Scientific include Agilent Technologies, Mettler-Toledo International, Illumina, Waters and Bio-Techne. Learn More about companies similar to Thermo Fisher Scientific.

How do I contact Thermo Fisher Scientific's investor relations team?

Thermo Fisher Scientific's physical mailing address is 168 Third Avenue, Waltham MA, 02451. The medical research company's listed phone number is (781) 622-1000 and its investor relations email address is [email protected]. The official website for Thermo Fisher Scientific is www.thermofisher.com. Learn More about contacing Thermo Fisher Scientific investor relations.